高危局限型前列腺癌立体定向体部放疗(SHARP)联盟:344例前瞻性治疗患者分析
该研究 pooled 了7项机构II期试验及前瞻性登记研究中344例高危前列腺癌(HRPCa)患者的个体数据,最短随访24个月,评估立体定向体部放疗(SBRT)的疗效与毒性。中位随访49.5个月,4年生化复发无生存(BCRFS)为81.7%(95%CI 77.2%-86.5%),4年无远处转移生存(DMFS)为89.1%(95%CI 85.3%-93.1%);晚期≥3级泌尿生殖毒性和胃肠道毒性粗发生率分别为2.3%和0.9%。结论支持SBRT用于HRPCa具有较好的疗效与毒性特征。
要点
- 4年BCRFS 81.7%,4年DMFS 89.1%,支持SBRT在高危前列腺癌中的疗效。
- 晚期≥3级泌尿生殖毒性和胃肠道毒性粗发生率分别为2.3%和0.9%。
核心结论
- 这些数据支持SBRT用于高危局限型前列腺癌具有较好的疗效与毒性特征。
- 仍需进一步前瞻性研究评估SBRT用于高危前列腺癌的最佳剂量和靶区范围。
研究设计与样本
- pooled 7项机构II期试验及前瞻性登记研究中344例高危局限型前列腺癌患者的个体数据,最短随访24个月。
- 采用Kaplan-Meier法估计BCRFS和DMFS,采用Fine和Gray竞争风险模型及Cox比例风险回归模型评估时间至BCR和时间至远处转移与预设变量的关联。
- 采用逻辑回归模型评估急性及晚期≥2级泌尿生殖和胃肠道毒性与年龄、分次剂量、ADT使用和淋巴结放疗的关联。
主要发现
- 估计4年BCRFS为81.7%(95%CI 77.2%-86.5%),4年DMFS为89.1%(95%CI 85.3%-93.1%)。
- 晚期≥3级泌尿生殖毒性和胃肠道毒性粗发生率分别为2.3%和0.9%。
临床怎么用
- 对于高危局限型前列腺癌,SBRT可作为具有较好疗效与毒性特征的放疗选择。
- 临床决策时需注意ADT使用和选择性淋巴结放疗的个体化考量,最佳剂量和靶区范围尚待前瞻性研究明确。
局限性
- 本研究为 pooled 分析,非随机对照设计,可能存在混杂偏倚。
- 随访时间有限,中位随访49.5个月,长期疗效和毒性尚未充分评估。
- 最佳剂量和靶区范围未确定,需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in high-risk prostate cancer (HRPCa) in a consortium of 7 institutional phase 2 trials and prospective registries. METHODS AND MATERIALS: Individual patient data were pooled for 344 patients with a minimum follow-up of 24 months. Biochemical recurrence-free survival (BCRFS) and distant metastasis-free survival (DMFS) were estimated using a Kaplan-Meier framework. Fine and Gray competing risk and Cox proportional hazards regression models were developed to assess the association between time to BCR and time to distant metastasis and prespecified variables of interest. Logistic regression models were developed to evaluate associations between acute and late grade ≥2 genitourinary and gastrointestinal and the following a priori-specified variables: age, dose per fraction, ADT use, and nodal radiation therapy. RESULTS: Median follow-up was 49.5 months. Seventy-two percent of patients received ADT, with a median duration of 9 months, and 19% received elective nodal radiation therapy. Estimated 4-year BCRFS and DMFS rates were 81.7% (95% CI, 77.2%-86.5%) and 89.1% (95% CI, 85.3%-93.1%). The crude incidences of late grade ≥3 genitourinary and gastrointestinal toxicity were 2.3% and 0.9%. CONCLUSIONS: These data support a favorable toxicity and efficacy profile for SBRT for HRPCa. Further prospective studies are needed to evaluate the optimal dose and target volume in the context of SBRT for HRPCa.
引用
- van Dams R, Jiang NY, Fuller DB, et al. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. Int J Radiat Oncol Biol Phys. 2021. PMID: 33493615. doi:10.1016/j.ijrobp.2021.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。